Vasculitis News and Research

Latest Vasculitis News and Research

Immune checkpoint inhibitors induce rheumatic and musculoskeletal diseases

Checkpoint inhibitor therapy is a form of cancer treatment immunotherapy currently under research. The therapy targets immune checkpoints, key regulators of the immune system that stimulate or inhibit its actions, which tumors can use to protect themselves from attacks by the immune system.

18 Jan 2019

Meta-analysis reveals effective treatment options for urticarial vasculitis

What treatments are available for patients with the rare inflammatory disease known as urticarial vasculitis? How effective are these treatments? Researchers from Charité - Universitätsmedizin Berlin embarked on a systematic review and meta-analysis to address these questions.

30 Oct 2018

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Bristol-Myers Squibb Company today announced four-year data from the Phase 3 CheckMate -067 clinical trial - the longest follow-up to date - which continues to demonstrate durable, long-term survival benefits with the first-line combination of Opdivo (nivolumab) and Yervoy (ipilimumab), versus Yervoy alone, in patients with advanced melanoma.

22 Oct 2018

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck, known as MSD outside the United States and Canada, today announced the first presentation of preliminary data from a Phase 1 clinical trial evaluating MK-1454, an investigational STING (stimulator of interferon genes) agonist, as monotherapy and in combination with KEYTRUDA (pembrolizumab), Merck's anti-PD-1 therapy, in patients with advanced solid tumors or lymphomas.

22 Oct 2018

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Merck, known as MSD outside the United States and Canada, today announced the first presentation of results from an interim analysis of KEYNOTE-057, a Phase 2 trial evaluating KEYTRUDA, Merck's anti-PD-1 therapy, for previously treated patients with high-risk non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ or CIS plus papillary disease (Cohort A).

22 Oct 2018

FDA approves update to Rituxan label to include information on treatment of rare forms of vasculitis

Genentech, a member of the Roche Group, announced today that the U.S. Food and Drug Administration has approved an update to the Rituxan® (rituximab) label to include information on follow up treatment of adult patients with Granulomatosis with Polyangiitis and Microscopic Polyangiitis who have achieved disease control with induction treatment.

22 Oct 2018

Health Care Apps and the Empowered Patient

An interview with Evergreen Life, discussing the importance of patient empowerment and how technology is allowing the NHS take a holistic approach to care.

From Evergreen Life 12 Sep 2018

CNDA approves KEYTRUDA for treatment of advanced melanoma

Merck, known as MSD outside the United States and Canada, today announced that KEYTRUDA, Merck's anti-PD-1 therapy, has been approved by the China National Drug Administration for the treatment of adult patients with unresectable or metastatic melanoma following failure of one prior line of therapy.

26 Jul 2018

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Merck, known as MSD outside the United States and Canada, announced today that the pivotal Phase 3 KEYNOTE-048 trial investigating KEYTRUDA, Merck's anti-PD-1 therapy, for first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma, met a primary endpoint of overall survival as monotherapy in patients whose tumors expressed PD-L1.

25 Jul 2018

Pfizer announces FDA approval of biosimilar to Neupogen

Pfizer Inc. today announced that the United States Food and Drug Administration has approved NIVESTYM (filgrastim-aafi), a biosimilar to Neupogen (filgrastim), for all eligible indications of the reference product.

23 Jul 2018

A systematic approach towards diagnosis and treatment of rheumatoid arthritis

Rheumatoid Arthritis: A systematic approach (edited by Dr. Syuichi Koarada) comprehensively covers each aspect of the pathology, diagnosis and treatment of rheumatoid arthritis.

26 Jun 2018

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has accepted for standard review a new supplemental Biologics License Application for KEYTRUDA, Merck's anti-PD-1 therapy, as adjuvant therapy in the treatment of patients with resected, high-risk stage III melanoma and granted a Prescription Drug User Fee Act, or target action, date of February 16, 2019.

25 Jun 2018

Study: Lenabasum has acceptable safety and tolerability in diffuse cutaneous systemic sclerosis

The results of an open label extension of a phase II study presented today at the Annual European Congress of Rheumatology, 2018, demonstrate that lenabasum continues to have acceptable safety and tolerability in diffuse cutaneous systemic sclerosis with no severe or serious adverse events.

18 Jun 2018

Opdivo plus low-dose Yervoy shows promising results in treating renal cell carcinoma patients

Bristol-Myers Squibb Company today announced patient-reported outcomes data from the Phase 3 CheckMate -214 trial in intermediate- and poor-risk patients with advanced renal cell carcinoma treated with the Immuno-Oncology combination Opdivo plus low-dose Yervoy versus sunitinib over a two-year follow-up period.

1 Jun 2018

Report highlights needs, experiences of people with rare autoimmune rheumatic diseases

People living with rare autoimmune rheumatic diseases are facing major obstacles to diagnosis, treatment and lifestyle according to a major new study published today [Wednesday 28th February].

28 Feb 2018

Texas Biomed and The Children’s Hospital of San Antonio join forces to cure mysterious condition

Texas Biomedical Research Institute and The Children's Hospital of San Antonio have joined forces to cure a mysterious condition called Kawasaki disease.

15 Feb 2018

Studies find alarming shortage of rheumatology workforce in future

Two new articles provide insights on the outlook of rheumatology in the United States, noting that the need for rheumatologists will greatly exceed the projected growth of the rheumatology workforce over the next 15 years.

5 Feb 2018

E-cigarettes may activate distinctive and potentially damaging immune responses, study reveals

A new study, published in the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine, suggests that e-cigarettes may stimulate distinct immune responses along with the same responses that cigarettes stimulate resulting in lung disease.

23 Oct 2017

Findings suggest e-cigarettes may be just as bad as traditional cigarettes

E-cigarettes appear to trigger unique immune responses as well as the same ones that cigarettes trigger that can lead to lung disease, according to new research published online in the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine.

20 Oct 2017

Research highlights need for expert treatment to manage subarachnoid hemorrhages

Research led by the head of the Barrow Neurological Institute and published in the July 20, 2017 issue of The New England Journal of Medicine reveals that subarachnoid hemorrhages, which are caused by ruptured brain aneurysms, account for 5-10 percent of all strokes and are best managed by experienced and dedicated experts at high-volume centers with neurosurgeons, endovascular surgeons and stroke neurologists.

17 Aug 2017

Vasculitis News and Research

Latest Vasculitis News and Research

Immune checkpoint inhibitors induce rheumatic and musculoskeletal diseases

Meta-analysis reveals effective treatment options for urticarial vasculitis

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

FDA approves update to Rituxan label to include information on treatment of rare forms of vasculitis

Health Care Apps and the Empowered Patient

CNDA approves KEYTRUDA for treatment of advanced melanoma

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Pfizer announces FDA approval of biosimilar to Neupogen

A systematic approach towards diagnosis and treatment of rheumatoid arthritis

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

Study: Lenabasum has acceptable safety and tolerability in diffuse cutaneous systemic sclerosis

Opdivo plus low-dose Yervoy shows promising results in treating renal cell carcinoma patients

Report highlights needs, experiences of people with rare autoimmune rheumatic diseases

Texas Biomed and The Children’s Hospital of San Antonio join forces to cure mysterious condition

Studies find alarming shortage of rheumatology workforce in future

E-cigarettes may activate distinctive and potentially damaging immune responses, study reveals

Findings suggest e-cigarettes may be just as bad as traditional cigarettes

Research highlights need for expert treatment to manage subarachnoid hemorrhages

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Vasculitis News and Research

Latest Vasculitis News and Research

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Newsletters you may be interested in